Nina Shah, MD

Title(s)Clinical Professor, Medicine
SchoolSchool of Medicine
Address400 Parnassus Avenue, #A450
San Francisco CA 94117
Phone415-353-2737
ORCID ORCID Icon0000-0002-1971-8173 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Harvard UniversityBA1998Cognitive Neuroscience
    New York University School of MedicineMD2002
    Columbia University2007Residency, Internal Medicine
    University of Texas MD Anderson Cancer Center2010Fellowship in Hematology/Oncology

    Collapse Overview 
    Collapse Overview
    Dr. Nina Shah is a hematologist who specializes in the treatment of multiple myeloma, a type of cancer affecting the blood marrow. She treats patients at the Hematology and Blood Marrow and Transplant Clinic.

    Nina received a bachelor’s degree in cognitive neuroscience at Harvard University, followed by a medical degree from New York University School of Medicine. She then completed a residency in internal medicine at Columbia University and a fellowship in hematology/oncology at University of Texas MD Anderson Cancer Center.

    Nina’s areas of professional interest include the intersection of immunology and oncology and helping patients fight multiple myeloma by boosting their immune systems.

    A clinical professor at UCSF, Dr. Shah belongs to the American Society of Clinical Oncology, the American Society of Hematology and the American Society for Blood and Marrow Transplantation. She speaks Bengali and Spanish.

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 2024 Jul 09; 8(13):3562-3575. Ledergor G, Fan Z, Wu K, McCarthy E, Hyrenius-Wittsten A, Starzinski A, Chang H, Bridge M, Kwek S, Cheung A, Bylsma S, Hansen E, Wolf J, Wong S, Shah N, Roybal KT, Martin T, Ye CJ, Fong L. PMID: 38574299.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    2. Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN. Blood Cancer J. 2024 Jul 08; 14(1):107. Chari A, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Silbermann R, Costa LJ, Anderson LD, Nathwani N, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Lin TS, Voorhees PM, Usmani SZ, Richardson PG. PMID: 38977707; PMCID: PMC11231363.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    3. Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma. Blood Adv. 2024 May 14; 8(9):2207-2216. Reyes KR, Liu YC, Huang CY, Banerjee R, Martin T, Wong SW, Wolf JL, Arora S, Shah N, Chari A, Chung A. PMID: 38429087; PMCID: PMC11061209.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    4. Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival. J Clin Oncol. 2024 Aug 10; 42(23):2757-2768. Pasquini MC, Wallace PK, Logan B, Kaur M, Tario JD, Howard A, Zhang Y, Brunstein C, Efebera Y, Geller N, Giralt S, Hari P, Horowitz MM, Koreth J, Krishnan A, Landau H, Somlo G, Shah N, Stadtmauer E, Vogl DT, Vesole DH, McCarthy PL, Hahn T. PMID: 38701390.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk. Blood Cancer J. 2024 Apr 22; 14(1):69. Callander NS, Silbermann R, Kaufman JL, Godby KN, Laubach J, Schmidt TM, Sborov DW, Medvedova E, Reeves B, Dhakal B, Rodriguez C, Chhabra S, Chari A, Bal S, Anderson LD, Dholaria BR, Nathwani N, Hari P, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Lin TS, Giri S, Costa LJ, Usmani SZ, Richardson PG, Voorhees PM. PMID: 38649340; PMCID: PMC11035596.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN. Am J Hematol. 2024 07; 99(7):1257-1268. Silbermann R, Laubach J, Kaufman JL, Sborov DW, Reeves B, Rodriguez C, Chari A, Costa LJ, Anderson LD, Nathwani N, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Orlowski RZ, Shain KH, Cowan AJ, Gries KS, Pei H, Cortoos A, Patel S, Lin TS, Voorhees PM, Usmani SZ, Richardson PG. PMID: 38622840.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    7. Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis. Bone Marrow Transplant. 2024 May; 59(5):699-704. Malek AE, Al-Juhaishi T, Milton DR, Ramdial JL, Daher M, Olson AL, Srour SA, Alatrash G, Oran B, Mehta RS, Khouri IF, Bashir Q, Shah N, Ciurea SO, Rondon G, Maadani F, Hosing C, Marin D, Kebriaei P, Rezvani K, Nieto Y, Anderlini P, Alousi AM, Faisal MS, Qazilbash MH, Popat UR, Champlin RE, Shpall EJ, Mulanovich VE, Ahmed S. PMID: 38355908.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401. Clin Cancer Res. 2023 12 01; 29(23):4784-4796. Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, Devine S, Somaiya Dutt P, Efebera Y, Geller N, Ghiasuddin H, Hematti P, Holmberg L, Howard A, Johnson B, Karagkouni D, Lazarus HM, Malek E, McCarthy P, McKenna D, Mendizabal A, Nooka A, Munshi N, O'Donnell L, Rapoport AP, Reese J, Rosenblatt J, Soiffer R, Stroopinsky D, Uhl L, Vlachos IS, Waller EK, Young JW, Pasquini MC, Avigan D. PMID: 37463058; PMCID: PMC10690096.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsCTClinical Trials
    9. Randomized phase 2 study of digital life coaching during transplantation for myeloma. Bone Marrow Transplant. 2023 12; 58(12):1406-1409. Banerjee R, Huang CY, Ryan C, Lee A, Brassil KJ, Moore J, Arora S, Chung A, Wong SW, Wolf J, Martin T, Dhruva A, Shah N. PMID: 37743374.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    10. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023 Oct; 10(10):e825-e837. Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, Nathwani N, Shah N, Bumma N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Dinner S, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG. PMID: 37708911.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    11. Impact of corticosteroids on efficacy of BCMA targeted CAR-T therapy in multiple myeloma. Leuk Lymphoma. 2023 Nov-Dec; 64(11):1888-1891. Duvalyan E, Shah N, Lo M, Martin T, Wolf JL, Chung A, Arora S, Huang CY, Wong SW. PMID: 37599633.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    12. Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study. Haematologica. 2023 08 01; 108(8):2249-2254. Dhakal B, Zhang MJ, Burns LJ, Tang X, Meyer C, Mau LW, Nooka AK, Stadtmauer E, Micallef IN, McGuirk J, Costa L, Juckett MB, Shah N, Champlin RE, Usmani SZ, Farag SS, Nishihori T, Roy V, Bodiford A, Barnes YJ, Drea EJ, Hari P, Hamadani M. PMID: 36601982; PMCID: PMC10388259.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. Value of embedded palliative care: outpatient palliative care and health care utilization for patients with hematologic malignancies. Blood Adv. 2023 07 11; 7(13):3146-3149. Tsang M, Bischoff K, Schoenbeck KL, Berry K, O'Riordan D, Fakhri B, Wong SW, Shah N, Olin R, Andreadis C, Vieaux J, Cohen E, Lopez NS, Mannis GN, Rabow M. PMID: 36809787; PMCID: PMC10362539.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Adv. 2023 06 27; 7(12):2746-2757. Ragon BK, Shah MV, D'Souza A, Estrada-Merly N, Gowda L, George G, de Lima M, Hashmi S, Kharfan-Dabaja MA, Majhail NS, Banerjee R, Saad A, Hildebrandt GC, Mian H, Abid MB, Battiwalla M, Lekakis LJ, Patel SS, Murthy HS, Nieto Y, Strouse C, Badawy SM, Al Hadidi S, Dholaria B, Aljurf M, Vesole DH, Lee CH, Pawarode A, Gergis U, Miller KC, Holmberg LA, Afrough A, Solh M, Munshi PN, Nishihori T, Anderson LD, Wirk B, Kaur G, Qazilbash MH, Shah N, Kumar SK, Usmani SZ. PMID: 36827681; PMCID: PMC10275699.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    15. Intensity of Cyclophosphamide-Based Bridging Therapy Before Chimeric Antigen Receptor T Cell Therapy in Myeloma. Transplant Cell Ther. 2023 08; 29(8):504.e1-504.e7. Zafar A, Huang CY, Lo M, Arora S, Chung A, Wong SW, Wolf J, Martin TG, Shah N, Banerjee R. PMID: 37244643.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    16. Significance of the pee-value: relevance of 24-hour urine studies for patients with myeloma. Leuk Lymphoma. 2023 06; 64(6):1186-1193. Natsuhara KH, Huang CY, Knoche J, Arora S, Chung A, Martin T, Wolf J, Wong SW, Shah N, Banerjee R. PMID: 37096638.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma. Cancer. 2023 07 15; 129(14):2179-2191. Bumma N, Dhakal B, Fraser R, Estrada-Merly N, Anderson K, Freytes CO, Hildebrandt GC, Holmberg L, Krem MM, Lee C, Lekakis L, Lazarus HM, Mian H, Murthy HS, Nathan S, Nishihori T, Parrondo R, Patel SS, Solh M, Strouse C, Vesole DH, Kumar S, Qazilbash MH, Shah N, D'Souza A, Sidana S. PMID: 37021929; PMCID: PMC10516285.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    18. Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial. Leuk Res. 2023 06; 129:107074. Delforge M, Otero PR, Shah N, Moshkovich O, Braverman J, Dhanda DS, Lanar S, Devlen J, Miera M, Gerould H, Campbell TB, Munshi NC. PMID: 37087950.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    19. Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma. Transplant Cell Ther. 2023 06; 29(6):350-355. Reyes KR, Huang CY, Lo M, Arora S, Chung A, Wong SW, Wolf J, Olin RL, Martin T, Shah N, Banerjee R. PMID: 36933659.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    20. Cytomegalovirus seropositivity is associated with improved responses to CD38 monoclonal antibody therapies in multiple myeloma: A single-centre retrospective study. Br J Haematol. 2023 06; 201(5):935-939. Ge AY, Huang CY, Banerjee R, Knoche J, Chung A, Arora S, Martin TG, Wolf J, Wong SW, Wiita AP, Shah N. PMID: 36846905.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    21. Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience. Transplant Cell Ther. 2023 04; 29(4):255-258. Kourelis T, Bansal R, Berdeja J, Siegel D, Patel K, Mailankody S, Htut M, Shah N, Wong SW, Sidana S, Cowan AJ, Alsina M, Cohen A, Holstein SA, Bergsagel L, Ailawadhi S, Raje N, Dhakal B, Rossi A, Lin Y. PMID: 36681151; PMCID: PMC10040426.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    22. Management of secondary immunodeficiency in hematological malignancies in the era of modern oncology. Crit Rev Oncol Hematol. 2023 Jan; 181:103896. Shah N, Mustafa SS, Vinh DC. PMID: 36528276.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    23. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. Transplant Cell Ther. 2023 03; 29(3):174.e1-174.e10. Chhabra S, Callander N, Watts NL, Costa LJ, Thapa B, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Anderson LD, Bal S, Dhakal B, Nathwani N, Shah N, Medvedova E, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Schmidt T, Orlowski RZ, Shain KH, Cowan AJ, Dholaria B, Cornell RF, Jerkins JH, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG, Voorhees PM. PMID: 36494017.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    24. Chimeric Antigen Receptor T-Cell Therapies: Barriers and Solutions to Access. JCO Oncol Pract. 2022 12; 18(12):800-807. Mikhael J, Fowler J, Shah N. PMID: 36130152.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCellsPHPublic Health
    25. Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study. Br J Haematol. 2022 11; 199(3):355-365. Sborov DW, Baljevic M, Reeves B, Laubach J, Efebera YA, Rodriguez C, Costa LJ, Chari A, Silbermann R, Holstein SA, Anderson LD, Kaufman JL, Shah N, Pei H, Patel S, Cortoos A, Bartlett JB, Vermeulen J, Lin TS, Voorhees PM, Richardson PG. PMID: 36111391; PMCID: PMC9825872.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    26. Antibody and T-cell responses by ultra-deep T-cell receptor immunosequencing after COVID-19 vaccination in patients with plasma cell dyscrasias. Br J Haematol. 2022 Nov; 199(4):520-528. Chung A, Banbury B, Vignali M, Huang CY, Asoori S, Johnson R, Kurtz T, Arora S, Wong SW, Shah N, Martin TG, Wolf JL. PMID: 36041779; PMCID: PMC9538250.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsPHPublic Health
    27. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2022 11 01; 40(31):3576-3586. D'Souza A, Shah N, Rodriguez C, Voorhees PM, Weisel K, Bueno OF, Pothacamury RK, Freise KJ, Yue S, Ross JA, Polepally AR, Talati C, Lee S, Jin Z, Buelow B, Vij R, Kumar S. PMID: 36029527; PMCID: PMC9622641.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCellsCTClinical Trials
    28. Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial. Leuk Res. 2022 09; 120:106921. Shah N, Delforge M, San-Miguel J, Moshkovich O, Braverman J, Dhanda DS, Lanar S, Miera M, Williams A, Murphy R, Devlen J, Hege K, Campbell TB, Munshi NC. PMID: 35930999.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    29. The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. Nat Commun. 2022 07 15; 13(1):4121. Ferguson ID, Patiño-Escobar B, Tuomivaara ST, Lin YT, Nix MA, Leung KK, Kasap C, Ramos E, Nieves Vasquez W, Talbot A, Hale M, Naik A, Kishishita A, Choudhry P, Lopez-Girona A, Miao W, Wong SW, Wolf JL, Martin TG, Shah N, Vandenberg S, Prakash S, Besse L, Driessen C, Posey AD, Mullins RD, Eyquem J, Wells JA, Wiita AP. PMID: 35840578; PMCID: PMC9287322.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    30. Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Blood Adv. 2022 07 12; 6(13):3991-3995. Kansagra A, Dispenzieri A, Fraser R, Estrada-Merly N, Sidana S, Nishihori T, Hansen DK, Anderson LD, Banerjee R, Bumma N, Dhakal B, Khouri J, Landau H, Lee C, Mian H, Nathan S, Savani B, Kumar S, Qazilbash M, Shah N, D'Souza A. PMID: 35507742; PMCID: PMC9278304.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    31. SNPs and PROs in myeloma: the most ambitious crossover of all time? Bone Marrow Transplant. 2022 10; 57(10):1475-1476. Banerjee R, Shah N. PMID: 35768572.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    32. A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplant. 2022 08; 57(8):1295-1303. Andersson BS, Thall PF, Ma J, Valdez BC, Bassett R, Chen J, Ahmed S, Alousi A, Bashir Q, Ciurea S, Gulbis A, Cool R, Kawedia J, Hosing C, Kebriaei P, Kornblau S, Myers A, Oran B, Rezvani K, Shah N, Shpall E, Parmar S, Popat UR, Nieto Y, Champlin RE. PMID: 35610308; PMCID: PMC9352570.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    33. Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma. Transplant Cell Ther. 2022 08; 28(8):446-454. Holstein SA, Asimakopoulos F, Azab AK, Bianchi G, Bhutani M, Crews LA, Cupedo T, Giles H, Gooding S, Hillengass J, John L, Kaiser S, Lee L, Maclachlan K, Pasquini MC, Pichiorri F, Shah N, Shokeen M, Shy BR, Smith EL, Verona R, Usmani SZ, McCarthy PL. PMID: 35605882; PMCID: PMC9357156.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    34. Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma. J Comp Eff Res. 2022 07; 11(10):737-749. Shah N, Mojebi A, Ayers D, Cope S, Dhanasiri S, Davies FE, Hari P, Patel P, Hege K, Dhanda D. PMID: 35485211.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    35. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 2022 04 12; 6(7):2045-2054. Kambhampati S, Sheng Y, Huang CY, Bylsma S, Lo M, Kennedy V, Natsuhara K, Martin T, Wolf J, Shah N, Wong SW. PMID: 34543400; PMCID: PMC9006279.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    36. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. Transplant Cell Ther. 2022 06; 28(6):284-293. Dhakal B, Shah N, Kansagra A, Kumar A, Lonial S, Garfall A, Cowan A, Poudyal BS, Costello C, Gay F, Cook G, Quach H, Einsele H, Schriber J, Hou J, Costa L, Aljurf M, Chaudhry M, Beksac M, Prince M, Mohty M, Janakiram M, Callander N, Biran N, Malhotra P, Otero PR, Moreau P, Abonour R, Iftikhar R, Silberman R, Mailankody S, Gregory T, Lin Y, Carpenter P, Hamadani M, Usmani S, Kumar S. PMID: 35306217.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    37. Digital Life Coaching During Stem Cell Transplantation: Development and Usability Study. JMIR Form Res. 2022 Mar 04; 6(3):e33701. Banerjee R, Huang CY, Dunn L, Knoche J, Ryan C, Brassil K, Jackson L, Patel D, Lo M, Arora S, Wong SW, Wolf J, Martin Iii T, Dhruva A, Shah N. PMID: 35039279; PMCID: PMC8933800.
      View in: PubMed   Mentions: 3  
    38. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma. Blood Adv. 2022 02 22; 6(4):1309-1318. Delforge M, Shah N, Miguel JSF, Braverman J, Dhanda DS, Shi L, Guo S, Yu P, Liao W, Campbell TB, Munshi NC. PMID: 34933328; PMCID: PMC8864645.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    39. Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT). Blood Cancer J. 2022 02 10; 12(2):27. Dispenzieri A, Krishnan A, Arendt B, Blackwell B, Wallace PK, Dasari S, Vogl DT, Efebera Y, Fei M, Geller N, Giralt S, Hahn T, Howard A, Kohlhagen M, Landau H, Hari P, Pasquini MC, Qazilbash MH, McCarthy P, Shah N, Vesole DH, Stadtmauer E, Murray D. PMID: 35145071; PMCID: PMC8831597.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    40. Complete response following treatment of plasma cell leukemia with venetoclax and dexamethasone: A case report. J Oncol Pharm Pract. 2022 Jul; 28(5):1244-1248. Vo K, Guan T, Banerjee R, Lo M, Young R, Shah N. PMID: 35084252.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    41. Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. Blood Adv. 2021 12 14; 5(23):5344-5348. Kennedy VE, Wong C, Huang CY, Kambhampati S, Wolf J, Martin TG, Shah N, Wong SW. PMID: 34644387; PMCID: PMC9153014.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    42. Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells. Front Oncol. 2021; 11:783703. Wong SW, Shah N, Ledergor G, Martin T, Wolf J, Shui AM, Huang CY, Martinez-Lopez J. PMID: 34938662; PMCID: PMC8685203.
      View in: PubMed   Mentions: 5  
    43. A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. Bone Marrow Transplant. 2022 02; 57(2):295-298. Tan CR, Estrada-Merly N, Landau H, Lekakis L, Banerjee R, Mian H, Usmani SZ, Hanbali A, Lazarus HM, Kyle RA, Dholaria B, Bal S, Strouse C, Murthy HS, Wirk B, Nishihori T, Kumar S, Shah N, Qazilbash M, D'Souza A. PMID: 34802047; PMCID: PMC8825695.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    44. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. Transplant Cell Ther. 2022 02; 28(2):83.e1-83.e9. Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agrawal V, Anderson LD, Aljurf M, Banerjee R, Bashey A, Battiwalla M, Beitinjaneh A, Chakraborty R, Chhabra S, Dhakal B, Dholaria B, Hashmi S, Janakiram M, Lee C, Lekakis L, Murthy HS, Parrondo R, Wangjam T, Usmani S, Shah N, Qazilbash M, D'Souza A. PMID: 34781066; PMCID: PMC8900987.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    45. Evaluation of subcutaneous daratumumab injections in the ambulatory care setting. J Oncol Pharm Pract. 2022 Dec; 28(8):1819-1825. Tam AH, Jung Y, Young R, Huang CY, Wolf J, Shah N, Wong SW, Martin TG, Lo M. PMID: 34647506.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    46. Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. Bone Marrow Transplant. 2022 01; 57(1):31-37. Pasvolsky O, Yeshurun M, Fraser R, Estrada-Merly N, Rozovski U, Shargian-Alon L, Assal A, Banerjee R, Bumma N, Gale RP, Hagen P, Holmberg L, Hossain NM, Lazarus HM, Lee C, Mian H, Miller KC, Nathan S, Nagler A, Nishihori T, Parrondo RD, Patel S, Schroeder MA, Usmani SZ, Wang T, Wirk B, Kumar S, Shah N, Qazilbash MH, D'Souza A. PMID: 34608275; PMCID: PMC8764606.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    47. Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma. J Hematol Oncol. 2021 08 17; 14(1):126. Martinez-Lopez J, Alonso R, Wong SW, Rios R, Shah N, Ruiz-Heredia Y, Sanchez-Pina JM, Sanchez R, Bahri N, Zamanillo I, Poza M, Buenache N, Encinas C, Juarez L, Miras F, Collado L, Barrio S, Martin T, Cedena MT, Wolf J. PMID: 34404440; PMCID: PMC8369640.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    48. FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma. Blood Adv. 2021 08 10; 5(15):3021-3031. Bigley AB, Spade S, Agha NH, Biswas S, Tang S, Malik MH, Dai L, Masoumi S, Patiño-Escobar B, Hale M, DiPierro G, Martell R, Hann B, Shah N, Wiita AP, Liu X. PMID: 34357379; PMCID: PMC8361460.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    49. Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older. Cancer. 2021 11 15; 127(22):4233-4239. Munshi PN, Vesole DH, St Martin A, Davila O, Kumar S, Qazilbash M, Shah N, Hari PN, D'Souza A. PMID: 34374445; PMCID: PMC8699178.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    50. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2021 08; 27(8):642-649. Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, Burroughs LM, Majhail N, Al-Homsi AS, Al-Kadhimi ZS, Bar M, Bertaina A, Boelens JJ, Champlin R, Chaudhury S, DeFilipp Z, Dholaria B, El-Jawahri A, Fanning S, Fraint E, Gergis U, Giralt S, Hamilton BK, Hashmi SK, Horn B, Inamoto Y, Jacobsohn DA, Jain T, Johnston L, Kanate AS, Kansagra A, Kassim A, Kean LS, Kitko CL, Knight-Perry J, Kurtzberg J, Liu H, MacMillan ML, Mahmoudjafari Z, Mielcarek M, Mohty M, Nagler A, Nemecek E, Olson TS, Oran B, Perales MA, Prockop SE, Pulsipher MA, Pusic I, Riches ML, Rodriguez C, Romee R, Rondon G, Saad A, Shah N, Shaw PJ, Shenoy S, Sierra J, Talano J, Verneris MR, Veys P, Wagner JE, Savani BN, Hamadani M, Carpenter PA. PMID: 34304802.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    51. Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2021 Jul; 35(7):2141. Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A. PMID: 34091601.
      View in: PubMed   Mentions:    Fields:    
    52. Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies. Future Oncol. 2021 Sep; 17(27):3549-3560. Shah N, Perales MA, Turtle CJ, Cairo MS, Cowan AJ, Saeed H, Budde LE, Tan A, Lee Z, Kai K, Marcondes MQ, Zalevsky J, Tagliaferri MA, Patel KK. PMID: 34154392.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    53. Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome. Leuk Lymphoma. 2021 11; 62(11):2600-2611. Banerjee R, Fakhri B, Shah N. PMID: 34151714.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    54. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Blood Cancer J. 2021 06 18; 11(6):116. Jagannath S, Lin Y, Goldschmidt H, Reece D, Nooka A, Senin A, Rodriguez-Otero P, Powles R, Matsue K, Shah N, Anderson LD, Streetly M, Wilson K, Le HV, Swern AS, Agarwal A, Siegel DS. PMID: 34145225; PMCID: PMC8213772.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    55. The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma. Transplant Cell Ther. 2021 10; 27(10):807-816. Holstein SA, Bahlis N, Bergsagel PL, Bhutani M, Bolli N, Brownstein C, Demolis P, Foureau D, Gay F, Ghobrial IM, Gormley N, Hillengass J, Kaiser M, Maus MV, Melenhorst JJ, Merz M, Dwyer MO, Paiva B, Pasquini MC, Shah N, Wong SW, Usmani SZ, McCarthy PL. PMID: 34107340; PMCID: PMC8478786.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    56. Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health. JCO Clin Cancer Inform. 2021 06; 5:668-678. Banerjee R, Shah N, Dicker AP. PMID: 34110929.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    57. Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2021 Jun; 35(6):1828. Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A. PMID: 33782538; PMCID: PMC8188513.
      View in: PubMed   Mentions:    Fields:    
    58. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. Circ Res. 2021 05 28; 128(11):1780-1801. Baik AH, Oluwole OO, Johnson DB, Shah N, Salem JE, Tsai KK, Moslehi JJ. PMID: 33934609; PMCID: PMC8159878.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimalsCells
    59. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. Cancer. 2021 06 01; 127(11):1816-1826. Martin TG, Shah N, Richter J, Vesole DH, Wong SW, Huang CY, Madduri D, Jagannath S, Siegel DS, Biran N, Wolf JL, Parekh S, Cho HJ, Munster P, Richard S, Ziti-Ljajic S, Chari A. PMID: 33735504; PMCID: PMC8252002.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    60. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma. Transplant Cell Ther. 2021 06; 27(6):477.e1-477.e7. Banerjee R, Marsal J, Huang CY, Lo M, Kambhampati S, Kennedy VE, Arora S, Wolf JL, Martin TG, Wong SW, Shah N. PMID: 33831353.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    61. When and How to Treat Relapsed Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2021 Mar; 41:358-375. Nathwani N, Bertamini L, Banerjee R, Gay F, Shah N, Krishnan A. PMID: 34010043.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    62. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021 02 25; 384(8):705-716. Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K, Rambaldi A, Reece D, Petrocca F, Massaro M, Connarn JN, Kaiser S, Patel P, Huang L, Campbell TB, Hege K, San-Miguel J. PMID: 33626253.
      View in: PubMed   Mentions: 750     Fields:    Translation:HumansCTClinical Trials
    63. Comparative Effectiveness Research for CAR-T Therapies in Multiple Myeloma: Appropriate Comparisons Require Careful Considerations of Data Sources and Patient Populations. Clin Drug Investig. 2021 Mar; 41(3):201-210. Shah N, Sussman M, Crivera C, Valluri S, Benner J, Jagannath S. PMID: 33598857.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    64. Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplant Cell Ther. 2021 05; 27(5):430.e1-430.e7. Ahmed S, Bashir Q, Bassett R, Poon MC, Valdez B, Konoplev S, Alousi AM, Andersson BS, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Kim S, Nieto Y, Olson A, Oran B, Parmar S, Qazilbash MH, Rezvani K, Shah N, Shpall EJ, Champlin R, Popat U. PMID: 33965187.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    65. Benzodiazepine and zolpidem prescriptions during autologous stem cell transplantation. EJHaem. 2021 May; 2(2):276-279. Banerjee R, Lazar AA, Dunn L, Knoche J, Lo M, Arora S, Wong SW, Wolf JL, Martin TG, Dhruva A, Shah N. PMID: 35845271; PMCID: PMC9175938.
      View in: PubMed   Mentions: 3  
    66. Incidence, management and outcomes of arterial and venous thrombosis after chimeric antigen receptor modified T cells for B cell lymphoma and multiple myeloma. Leuk Lymphoma. 2021 04; 62(4):1003-1006. Parks AL, Kambhampati S, Fakhri B, Andreadis C, Gray L, Wong SW, Shah N, Fang MC. PMID: 33258699; PMCID: PMC8012226.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    67. Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. Br J Haematol. 2020 11; 191(3):442-452. Dhakal B, D'Souza A, Callander N, Chhabra S, Fraser R, Davila O, Anderson K, Assal A, Badawy SM, Berdeja J, Cerny J, Comenzo R, Chakraborty R, Peter Gale R, Kamble R, Kharfan-Dabaja MA, Krem M, Ganguly S, Janakiram M, Kansagra A, Munker R, Murthy H, Patel S, Kumar S, Shah N, Qazilbash M, Hari P. PMID: 33094839; PMCID: PMC7990054.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    68. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer. 2020 12 01; 126(23):5077-5087. Munshi PN, Vesole D, Jurczyszyn A, Zaucha JM, St Martin A, Davila O, Agrawal V, Badawy SM, Battiwalla M, Chhabra S, Copelan E, Kharfan-Dabaja MA, Farhadfar N, Ganguly S, Hashmi S, Krem MM, Lazarus HM, Malek E, Meehan K, Murthy HS, Nishihori T, Olin RL, Olsson RF, Schriber J, Seo S, Shah G, Solh M, Tay J, Kumar S, Qazilbash MH, Shah N, Hari PN, D'Souza A. PMID: 32965680; PMCID: PMC8063213.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    69. African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. Cancer. 2021 01 01; 127(1):82-92. Badar T, Hari P, Dávila O, Fraser R, Wirk B, Dhakal B, Freytes CO, Rodriguez Valdes C, Lee C, Vesole DH, Malek E, Hildebrandt GC, Landau H, Murthy HS, Lazarus HM, Berdeja JG, Meehan KR, Solh M, Diaz MA, Kharfan-Dabaja MA, Callander NS, Farhadfar N, Bashir Q, Kamble RT, Vij R, Munker R, Kyle RA, Chhabra S, Hashmi S, Ganguly S, Jagannath S, Nishihori T, Nieto Y, Kumar S, Shah N, D'Souza A. PMID: 32966625; PMCID: PMC7736245.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    70. Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. Transplant Cell Ther. 2021 01; 27(1):6-20. Dholaria B, Savani BN, Hamilton BK, Oran B, Liu HD, Tallman MS, Ciurea SO, Holtzman NG, Ii GLP, Devine SM, Mannis G, Grunwald MR, Appelbaum F, Rodriguez C, El Chaer F, Shah N, Hashmi SK, Kharfan-Dabaja MA, DeFilipp Z, Aljurf M, AlShaibani A, Inamoto Y, Jain T, Majhail N, Perales MA, Mohty M, Hamadani M, Carpenter PA, Nagler A. PMID: 32966881.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    71. The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements. PLoS One. 2020; 15(8):e0237155. Cedena MT, Martin-Clavero E, Wong S, Shah N, Bahri N, Alonso R, Barcenas C, Valeri A, Salazar Tabares J, Sanchez-Pina J, Cuellar C, Martin T, Wolf J, Lahuerta JJ, Martinez-Lopez J. PMID: 32866200; PMCID: PMC7458342.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    72. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020 08 20; 136(8):936-945. Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, Nathwani N, Shah N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Murphy S, Lutska Y, Pei H, Ukropec J, Vermeulen J, de Boer C, Hoehn D, Lin TS, Richardson PG. PMID: 32325490; PMCID: PMC7441167.
      View in: PubMed   Mentions: 254     Fields:    Translation:HumansCTClinical Trials
    73. Modified Hyper-CVAD With Proteasome Inhibition for Multiple Myeloma: A Single-Center Retrospective Analysis. Clin Lymphoma Myeloma Leuk. 2020 12; 20(12):e961-e985. Narayan R, Galligan D, Lazar AA, Kim S, Fong R, Tan M, Lo M, Arora S, Shah N, Wong SW, Martin T, Wolf J. PMID: 32839138.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    74. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. Blood Adv. 2020 07 28; 4(14):3295-3301. Martinez-Lopez J, Wong SW, Shah N, Bahri N, Zhou K, Sheng Y, Huang CY, Martin T, Wolf J. PMID: 32706892; PMCID: PMC7391154.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    75. CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma. Blood Adv. 2020 07 14; 4(13):2899-2911. Ramkumar P, Abarientos AB, Tian R, Seyler M, Leong JT, Chen M, Choudhry P, Hechler T, Shah N, Wong SW, Martin TG, Wolf JL, Roybal KT, Pahl A, Taunton J, Wiita AP, Kampmann M. PMID: 32589729; PMCID: PMC7362346.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    76. Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020 10; 26(10):1784-1802. Bar M, Ott SM, Lewiecki EM, Sarafoglou K, Wu JY, Thompson MJ, Vaux JJ, Dean DR, Saag KG, Hashmi SK, Inamoto Y, Dholaria BR, Kharfan-Dabaja MA, Nagler A, Rodriguez C, Hamilton BK, Shah N, Flowers MED, Savani BN, Carpenter PA. PMID: 32653624.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    77. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. J Immunother Cancer. 2020 07; 8(2). Shah N, Aiello J, Avigan DE, Berdeja JG, Borrello IM, Chari A, Cohen AD, Ganapathi K, Gray L, Green D, Krishnan A, Lin Y, Manasanch E, Munshi NC, Nooka AK, Rapoport AP, Smith EL, Vij R, Dhodapkar M. PMID: 32661116; PMCID: PMC7359060.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    78. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol. 2021; 144(1):74-81. Olson AL, Saliba RM, Oran B, Chen J, Alousi A, Ahmed S, Bashir Q, Ciurea SO, Hosing C, Seon Im J, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Parmar S, Rezvani K, Shah N, Shpall E, Srour SA, Qazilbash M, Andersson BS, Champlin R, Popat UR. PMID: 32604096.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    79. Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant. 2020 10; 26(10):e247-e255. Holstein SA, Howard A, Avigan D, Bhutani M, Cohen AD, Costa LJ, Dhodapkar MV, Gay F, Gormley N, Green DJ, Hillengass J, Korde N, Li Z, Mailankody S, Neri P, Parekh S, Pasquini MC, Puig N, Roodman GD, Samur MK, Shah N, Shah UA, Shi Q, Spencer A, Suman VJ, Usmani SZ, McCarthy PL. PMID: 32589921; PMCID: PMC7529908.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    80. Advances in CAR T-cell therapy for the treatment of multiple myeloma. Clin Adv Hematol Oncol. 2020 Jun; 18(6):316-318. Shah N. PMID: 32649653.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    81. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. Blood Adv. 2020 05 26; 4(10):2163-2171. Alonso R, Cedena MT, Wong S, Shah N, Ríos-Tamayo R, Moraleda JM, López-Jiménez J, García C, Bahri N, Valeri A, Sánchez R, Collado-Yurrita L, Martin T, Wolf J, Lahuerta JJ, Martínez-López J. PMID: 32433744; PMCID: PMC7252556.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    82. Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma. Nat Commun. 2020 04 22; 11(1):1931. Huang HH, Ferguson ID, Thornton AM, Bastola P, Lam C, Lin YT, Choudhry P, Mariano MC, Marcoulis MD, Teo CF, Malato J, Phojanakong PJ, Martin TG, Wolf JL, Wong SW, Shah N, Hann B, Brooks AN, Wiita AP. PMID: 32321912; PMCID: PMC7176739.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    83. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2020 12; 34(12):3338-3347. Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A. PMID: 32313109; PMCID: PMC7572530.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    84. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020 04; 34(4):985-1005. Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. PMID: 32055000; PMCID: PMC7214244.
      View in: PubMed   Mentions: 160     Fields:    Translation:HumansCells
    85. A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma. Leuk Lymphoma. 2020 05; 61(5):1211-1219. Kambhampati S, Galligan D, Huang CY, Wong S, Wolf J, Martin T, Shah N. PMID: 31928108.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    86. The Struggle Is Real: Practice Patterns for the "Myelennial" Generation. JCO Oncol Pract. 2020 01; 16(1):17-18. Shah N. PMID: 32039662.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    87. CAR T-cell therapy: is it prime time in myeloma? Hematology Am Soc Hematol Educ Program. 2019 12 06; 2019(1):260-265. Sidana S, Shah N. PMID: 31808895; PMCID: PMC6913444.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    88. Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma. Biol Blood Marrow Transplant. 2020 05; 26(5):876-883. Shah EE, Young RP, Wong SW, Damon LE, Wolf JL, Shah ND, Leavitt AD, Loeffler P, Martin TG. PMID: 31785375.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    89. Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database. Cancer. 2020 02 15; 126(4):808-813. Fakhri B, Fiala MA, Shah N, Vij R, Wildes TM. PMID: 31721140; PMCID: PMC6992490.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    90. CAR T-cell therapy: is it prime time in myeloma? Blood Adv. 2019 11 12; 3(21):3473-3480. Sidana S, Shah N. PMID: 31714964; PMCID: PMC6855102.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    91. Fixed-Duration Versus Until Disease Progression: How Long Should Initial Treatment of Multiple Myeloma Last? J Natl Compr Canc Netw. 2019 11; 17(11.5):1430-1432. Efebera YA, Shah N. PMID: 31766020.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    92. DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma. Leukemia. 2020 03; 34(3):938-941. Choudhry P, Mariano MC, Geng H, Martin TG, Wolf JL, Wong SW, Shah N, Wiita AP. PMID: 31595037; PMCID: PMC7214267.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    93. Estimation of minimally important differences and responder definitions for EORTC QLQ-MY20 scores in multiple myeloma patients. Eur J Haematol. 2019 Nov; 103(5):500-509. Sully K, Trigg A, Bonner N, Moreno-Koehler A, Trennery C, Shah N, Yucel E, Panjabi S, Cocks K. PMID: 31444815; PMCID: PMC6852250.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    94. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol. 2019 May; 6(5):e266-e275. Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH. PMID: 30910541; PMCID: PMC9446704.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    95. Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):332-344. Ghobrial I, Cruz CH, Garfall A, Shah N, Munshi N, Kaufman J, Boise LH, Morgan G, Adalsteinsson VA, Manier S, Pillai R, Malavasi F, Lonial S. PMID: 31023594.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    96. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. J Clin Oncol. 2019 03 01; 37(7):589-597. Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Knust K, Landau H, Brunstein C, McCarthy P, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Giralt S, Somlo G, Krishnan A. PMID: 30653422; PMCID: PMC6553842.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansCTClinical Trials
    97. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biol Blood Marrow Transplant. 2019 05; 25(5):1039-1044. Maymani H, Lin P, Saliba RM, Popat U, Bashir Q, Shah N, Patel K, Parmar S, Kebriaei P, Hosing C, Ciurea S, Andersson B, Shpall E, Champlin R, Srour SA, Qazilbash MH. PMID: 30639822; PMCID: PMC7053532.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    98. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. Biol Blood Marrow Transplant. 2019 04; 25(4):683-688. Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P. PMID: 30579965; PMCID: PMC6453717.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    99. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant. 2019 07; 54(7):1089-1093. Gowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, Manasanch EE, Shah A, Thomas SK, Parmar S, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. PMID: 30446740; PMCID: PMC8393277.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    100. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol. 2018 Nov; 5(11):e532-e542. Popat UR, Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Rezvani K, Qazilbash MH, Shah N, Srour SA, Shpall EJ, Champlin RE, Andersson BS. PMID: 30389035; PMCID: PMC6317874.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    101. Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. Biol Blood Marrow Transplant. 2018 12; 24(12):2443-2449. Scott EC, Hari P, Kumar S, Fraser R, Davila O, Shah N, Gale RP, Diaz MA, Agrawal V, Cornell RF, Ganguly S, Akpek G, Freytes C, Hashmi S, Malek E, Kamble RT, Lazarus H, Solh M, Usmani SZ, Kanate AS, Saad A, Chhabra S, Gergis U, Cerny J, Kyle RA, Lee C, Kindwall-Keller T, Assal A, Hildebrandt GC, Holmberg L, Maziarz RT, Nishihori T, Seo S, Kumar S, Mark T, D'Souza A. PMID: 30142419; PMCID: PMC6293469.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    102. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma. 2019 02; 60(2):442-452. Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH. PMID: 30032678.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    103. ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. Biol Blood Marrow Transplant. 2018 06; 24(6):1119-1124. Hashmi SK, Lee SJ, Savani BN, Burns L, Wingard JR, Perales MA, Palmer J, Chow E, Meyer E, Marks D, Mohty M, Inamoto Y, Rodriguez C, Nagler A, Sauter C, Komanduri KV, Pidala J, Hamadani M, Johnston L, Shah N, Shaughnessy P, Hamilton BK, Majhail N, Kharfan-Dabaja MA, Schriber J, DeFilipp Z, Tarlock KG, Fanning S, Curtin P, Rizzo JD, Carpenter PA. PMID: 29608957.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    104. Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. Bone Marrow Transplant. 2018 03; 53(3):315-325. Ragon BK, Mehta RS, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. PMID: 29269797; PMCID: PMC8360209.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    105. Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma. Qual Life Res. 2018 Apr; 27(4):979-985. Shah N, Shi Q, Giralt S, Williams L, Bashir Q, Qazilbash M, Champlin RE, Cleeland CS, Wang XS. PMID: 29260444.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    106. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant. 2018 06; 24(6):1163-1171. Casulo C, Friedberg JW, Ahn KW, Flowers C, DiGilio A, Smith SM, Ahmed S, Inwards D, Aljurf M, Chen AI, Choe H, Cohen J, Copelan E, Farooq U, Fenske TS, Freytes C, Gaballa S, Ganguly S, Jethava Y, Kamble RT, Kenkre VP, Lazarus H, Lazaryan A, Olsson RF, Rezvani AR, Rizzieri D, Seo S, Shah GL, Shah N, Solh M, Sureda A, William B, Cumpston A, Zelenetz AD, Link BK, Hamadani M. PMID: 29242111; PMCID: PMC5993598.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansPHPublic Health
    107. Histologic Grade 1 Is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease. Am J Surg Pathol. 2017 Nov; 41(11):1483-1490. Im JS, Abraham SC, Saliba RM, Rondon G, Ross WA, Rashid A, Shpall EJ, Popat U, Qazilbash MH, Hosing C, Oran B, Shah N, Tewari P, Nieto Y, Kebriaei P, Champlin RE, Alousi AM. PMID: 28834808; PMCID: PMC9994461.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    108. Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. Eur J Haematol. 2017 Dec; 99(6):532-535. Shah N, Cornelison AM, Saliba R, Ahmed S, Nieto YL, Bashir Q, Parmar S, Hosing C, Popat U, Shpall EJ, Champlin RE, Qazilbash M. PMID: 28895206; PMCID: PMC8415170.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    109. A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. Leuk Lymphoma. 2018 02; 59(2):515-518. Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. PMID: 28673185.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    110. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer. 2017 Sep 15; 123(18):3568-3575. Veltri LW, Milton DR, Delgado R, Shah N, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea S, Hosing C, Lee HC, Manasanch E, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. PMID: 28513828; PMCID: PMC5656242.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    111. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Lancet Haematol. 2017 Jun; 4(6):e283-e292. Nieto Y, Valdez BC, Pingali SR, Bassett R, Delgado R, Nguyen J, Shah N, Popat U, Jones RB, Andersson BS, Gulbis A, Ahmed S, Bashir Q, Parmar S, Patel K, Myers A, Rondon G, Orlowski RZ, Champlin R, Qazilbash M. PMID: 28522110; PMCID: PMC5844223.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    112. Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. Biol Blood Marrow Transplant. 2017 Aug; 23(8):1359-1366. Mehta RS, Saliba RM, Cao K, Kaur I, Rezvani K, Chen J, Olson A, Parmar S, Shah N, Marin D, Alousi A, Hosing C, Popat U, Kebriaei P, Champlin R, de Lima M, Skerrett D, Burke E, Shpall EJ, Oran B. PMID: 28506845; PMCID: PMC6453532.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCellsCTClinical Trials
    113. Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Br J Haematol. 2017 05; 177(4):567-577. Thompson PA, Stingo F, Keating MJ, Wierda WG, O'Brien SM, Estrov Z, Ledesma C, Rezvani K, Qazilbash M, Shah N, Parmar S, Popat U, Anderlini P, Yago N, Ciurea SO, Kebriaei P, Champlin R, Shpall EJ, Hosing CM. PMID: 28295181; PMCID: PMC7394482.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    114. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol. 2017 05; 177(3):457-466. Shah N, Li L, McCarty J, Kaur I, Yvon E, Shaim H, Muftuoglu M, Liu E, Orlowski RZ, Cooper L, Lee D, Parmar S, Cao K, Sobieiski C, Saliba R, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard C, Qazilbash M, Champlin R, Rezvani K, Shpall EJ. PMID: 28295190; PMCID: PMC5856008.
      View in: PubMed   Mentions: 98     Fields:    Translation:HumansCellsCTClinical Trials
    115. Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma. Transfusion. 2017 04; 57(4):1052-1057. Ge I, Saliba RM, Maadani F, Popat UR, Qazilbash MH, Ravi Pingali S, Shah N, Ahmed S, Bashir Q, Nieto Y, Champlin RE, Hosing C. PMID: 28185276; PMCID: PMC8253453.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    116. Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Apr; 23(4):581-587. Varma A, Biritxinaga L, Saliba RM, Stich M, Jauch SF, Afrough A, Honhar M, Popat UR, Shafi MA, Shah N, Bashir Q, Dinh Y, Hosing C, Champlin RE, Qazilbash MH. PMID: 28063964; PMCID: PMC5749257.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    117. Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma. Eur J Haematol. 2017 Mar; 98(3):263-268. Badar T, Srour S, Bashir Q, Shah N, Al-Atrash G, Hosing C, Popat U, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. PMID: 27862330; PMCID: PMC8318336.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    118. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biol Blood Marrow Transplant. 2017 Feb; 23(2):285-292. Kebriaei P, Bassett R, Lyons G, Valdez B, Ledesma C, Rondon G, Oran B, Ciurea S, Alousi A, Popat U, Patel K, Ahmed S, Olson A, Bashir Q, Shah N, Jones R, Marin D, Rezvani K, Nieto Y, Khouri I, Qazilbash M, Hosing C, Shpall E, Champlin RE, Andersson BS. PMID: 27816651; PMCID: PMC5926804.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    119. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer. 2016 Dec 15; 122(24):3831-3837. Mian I, Milton DR, Shah N, Nieto Y, Popat UR, Kebriaei P, Parmar S, Oran B, Shah JJ, Manasanch EE, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. PMID: 27680710; PMCID: PMC5138119.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    120. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. Am J Hematol. 2016 10; 91(10):E442-7. Gaballa S, Saliba RM, Srour S, Lu G, Brammer JE, Shah N, Bashir Q, Patel K, Bock F, Parmar S, Hosing C, Popat U, Delgado R, Rondon G, Shah JJ, Manasanch EE, Orlowski RZ, Champlin R, Qazilbash MH. PMID: 27420405; PMCID: PMC5031524.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    121. Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. Biol Blood Marrow Transplant. 2016 11; 22(11):1915-1925. Palmer J, McCune JS, Perales MA, Marks D, Bubalo J, Mohty M, Wingard JR, Paci A, Hassan M, Bredeson C, Pidala J, Shah N, Shaughnessy P, Majhail N, Schriber J, Savani BN, Carpenter PA. PMID: 27481448.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    122. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer. 2016 Nov 15; 122(21):3316-3326. Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Lombardi L, Alatrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri I, Champlin RE, Ciurea SO. PMID: 27404668; PMCID: PMC5459484.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    123. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood. 2016 07 14; 128(2):297-312. Sekine T, Marin D, Cao K, Li L, Mehta P, Shaim H, Sobieski C, Jones R, Oran B, Hosing C, Rondon G, Alsuliman A, Paust S, Andersson B, Popat U, Kebriaei P, Muftuoglu M, Basar R, Kondo K, Nieto Y, Shah N, Olson A, Alousi A, Liu E, Sarvaria A, Parmar S, Armstrong-James D, Imahashi N, Molldrem J, Champlin R, Shpall EJ, Rezvani K. PMID: 27247137; PMCID: PMC4946205.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    124. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer. 2016 09 01; 122(17):2680-8. Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. PMID: 27203405; PMCID: PMC4992444.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    125. Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biol Blood Marrow Transplant. 2016 May; 22(5):961-5. Aung FM, Lichtiger B, Rondon G, Yin CC, Alousi A, Ahmed S, Andersson BS, Bashir Q, Ciurea SO, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Shpall EJ, Champlin RE, Popat U. PMID: 26921820; PMCID: PMC7176024.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    126. Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. Leuk Lymphoma. 2016 07; 57(7):1607-15. Thompson PA, Perera T, Marin D, Oran B, Popat U, Qazilbash M, Shah N, Parmar S, Rezvani K, Olson A, Kebriaei P, Anderlini P, Rondon G, Alousi A, Ciurea S, Champlin RE, Bajel A, Szer J, Shpall EJ, Ritchie D, Hosing CM. PMID: 26472485; PMCID: PMC6545894.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    127. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):122-8. Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B. PMID: 26795083; PMCID: PMC9754636.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    128. Better allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica. 2015 Oct; 100(10):1361-70. Oran B, Cao K, Saliba RM, Rezvani K, de Lima M, Ahmed S, Hosing CM, Popat UR, Carmazzi Y, Kebriaei P, Nieto Y, Rondon G, Willis D, Shah N, Parmar S, Olson A, Moore B, Marin D, Mehta R, Fernández-Viña M, Champlin RE, Shpall EJ. PMID: 26250579; PMCID: PMC4591769.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    129. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2015 Nov; 15(11):687-93. Kazmi SM, Nusrat M, Gunaydin H, Cornelison AM, Shah N, Kebriaei P, Nieto Y, Parmar S, Popat UR, Oran B, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH, Bashir Q. PMID: 26361647; PMCID: PMC4644689.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    130. Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis. Biol Blood Marrow Transplant. 2016 Feb; 22(2):226-231. Shah N, Shi Q, Williams LA, Mendoza TR, Wang XS, Reuben JM, Dougherty PM, Bashir Q, Qazilbash MH, Champlin RE, Cleeland CS, Giralt SA. PMID: 26253006; PMCID: PMC4716870.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    131. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1914-20. Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. PMID: 26071868; PMCID: PMC4781754.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    132. Umbilical cord blood: advances and opportunities. Introduction. Cytotherapy. 2015 Jun; 17(6):693-694. Shah N, Boelens JJ. PMID: 25946725.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    133. Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clin Lymphoma Myeloma Leuk. 2015 Aug; 15(8):472-6. El Fakih R, Fox P, Popat U, Nieto Y, Shah N, Parmar S, Oran B, Ciurea S, Kebriaei P, Hosing C, Ahmed S, Shah J, Orlowski R, Champlin R, Qazilbash M, Bashir Q. PMID: 25963284; PMCID: PMC4516682.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    134. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood. 2015 May 07; 125(19):2885-92. Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ. PMID: 25778529; PMCID: PMC4424412.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCells
    135. Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1155-66. Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, Sengsayadeth S, Abidi M, Hari P, Mohty M, Chen YB, Koreth J, Landau H, Lazarus H, Leather H, Majhail N, Nath R, Osman K, Perales MA, Schriber J, Shaughnessy P, Vesole D, Vij R, Wingard J, Giralt S, Savani BN, American Society for Blood and Marrow Transplantation. PMID: 25769794.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    136. General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1284-90. Saliba RM, Rezvani K, Leen A, Jorgensen J, Shah N, Hosing C, Parmar S, Oran B, Olson A, Rondon G, Chen J, Martinez C, Hamdi A, Mehta RS, Chemaly RF, Saunders IM, Bollard CM, Shpall EJ. PMID: 25708219; PMCID: PMC4798431.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    137. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. Biol Blood Marrow Transplant. 2015 May; 21(5):906-12. Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, Shah N, Ahmed S, Oran B, Al Atrash G, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin RE. PMID: 25667989; PMCID: PMC4825327.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    138. Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo. Blood. 2015 Feb 26; 125(9):1502-6. Parmar S, Liu X, Najjar A, Shah N, Yang H, Yvon E, Rezvani K, McNiece I, Zweidler-McKay P, Miller L, Wolpe S, Blazar BR, Shpall EJ. PMID: 25428215; PMCID: PMC4342362.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimalsCells
    139. Concise review: umbilical cord blood transplantation: past, present, and future. Stem Cells Transl Med. 2014 Dec; 3(12):1435-43. Munoz J, Shah N, Rezvani K, Hosing C, Bollard CM, Oran B, Olson A, Popat U, Molldrem J, McNiece IK, Shpall EJ. PMID: 25378655; PMCID: PMC4250219.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    140. Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective. Clin Lymphoma Myeloma Leuk. 2014 Sep; 14 Suppl:S18-22. Shah N, Rezvani K, Hosing C, Kebriaei P, Wierda W, Cooper L, Shpall E. PMID: 25486950; PMCID: PMC4844462.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    141. Subclinical peripheral neuropathy in patients with multiple myeloma before chemotherapy is correlated with decreased fingertip innervation density. J Clin Oncol. 2014 Oct 01; 32(28):3156-62. Kosturakis AK, He Z, Li Y, Boyette-Davis JA, Shah N, Thomas SK, Zhang H, Vichaya EG, Wang XS, Wendelschafer-Crabb G, Kennedy WR, Simone DA, Cleeland CS, Dougherty PM. PMID: 25154818; PMCID: PMC4171359.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    142. Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma. Leuk Lymphoma. 2015 Mar; 56(3):602-7. Glitza IC, Lu G, Shah R, Bashir Q, Shah N, Champlin RE, Shah J, Orlowski RZ, Qazilbash MH. PMID: 24844357; PMCID: PMC4333105.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    143. Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood. 2014 Sep 25; 124(13):2034-45. Khoder A, Sarvaria A, Alsuliman A, Chew C, Sekine T, Cooper N, Mielke S, de Lavallade H, Muftuoglu M, Fernandez Curbelo I, Liu E, Muraro PA, Alousi A, Stringaris K, Parmar S, Shah N, Shaim H, Yvon E, Molldrem J, Rouce R, Champlin R, McNiece I, Mauri C, Shpall EJ, Rezvani K. PMID: 25051962; PMCID: PMC4186534.
      View in: PubMed   Mentions: 103     Fields:    Translation:HumansCells
    144. Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma. Leuk Lymphoma. 2015 Feb; 56(2):533-5. Gul Z, Bashir Q, Cremer M, Yusuf SW, Gunaydin H, Arora S, Slone S, Nieto Y, Sherwani N, Parmar S, Shah N, Dinh YT, Hosing CM, Popat UR, Kebriaei P, Shpall EJ, Giralt SA, Champlin RE, Qazilbash MH. PMID: 24882259.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    145. Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):e105-9. Mehta RS, Di Stasi A, Hosing C, Shah N, Rezvani K, Alousi A, O'Brien S, Wierda W, Keating M, Shpall EJ. PMID: 24502832; PMCID: PMC4840930.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    146. Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy. 2014 Jan; 16(1):90-100. Parmar S, Liu X, Tung SS, Robinson SN, Rodriguez G, Cooper LJ, Yang H, Shah N, Yang H, Konopleva M, Molldrem JJ, Garcia-Manero G, Najjar A, Yvon E, McNiece I, Rezvani K, Savoldo B, Bollard CM, Shpall EJ. PMID: 24480547; PMCID: PMC4124936.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    147. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One. 2013; 8(10):e76781. Shah N, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJ, Decker WK, Li S, Robinson SN, Sekine T, Parmar S, Gribben J, Wang M, Rezvani K, Yvon E, Najjar A, Burks J, Kaur I, Champlin RE, Bollard CM, Shpall EJ. PMID: 24204673; PMCID: PMC3800010.
      View in: PubMed   Mentions: 92     Fields:    Translation:HumansAnimalsCells
    148. Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. Cytotherapy. 2014 Jan; 16(1):84-9. Robinson SN, Thomas MW, Simmons PJ, Lu J, Yang H, Parmar S, Liu X, Shah N, Martín-Antonio B, Bollard C, Dotti G, Savoldo B, Cooper LJ, Najjar A, Rezvani K, Kaur I, McNiece IK, Champlin RE, Miller LP, Zweidler-McKay PA, Shpall EJ. PMID: 24094497; PMCID: PMC3883688.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    149. A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. Biol Blood Marrow Transplant. 2013 Oct; 19(10):1453-8. Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH. PMID: 23872222; PMCID: PMC4157818.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    150. Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2013 Aug; 19(8):1227-32. Sasaki K, Lu G, Saliba RM, Bashir Q, Hosing C, Popat U, Shah N, Parmar S, Dinh Y, Ahmed S, Shpall EJ, Kebriaei P, Shah JJ, Orlowski RZ, Champlin R, Qazilbash MH. PMID: 23733001; PMCID: PMC4150684.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    151. Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy. Cancer Chemother Pharmacol. 2013 Jun; 71(6):1531-40. Vichaya EG, Wang XS, Boyette-Davis JA, Mendoza TR, He Z, Thomas SK, Shah N, Williams LA, Cleeland CS, Dougherty PM. PMID: 23543296; PMCID: PMC3669643.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    152. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol. 2013 Mar; 160(6):798-805. Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, Ciurea SO, de Lima MJ, Hosing C, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Khouri I, Champlin RE, Popat U. PMID: 23330820; PMCID: PMC4078723.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    153. Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC. PLoS One. 2012; 7(12):e51390. Decker WK, Shah N, Xing D, Lapushin R, Li S, Robinson SN, Yang H, Parmar S, Halpert MM, Keating MJ, Gribben JG, Molldrem JJ, Shpall EJ, Wierda WG. PMID: 23284688; PMCID: PMC3526610.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    154. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med. 2012 Dec 13; 367(24):2305-15. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. PMID: 23234514; PMCID: PMC3805360.
      View in: PubMed   Mentions: 206     Fields:    Translation:HumansCellsCTClinical Trials
    155. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant. 2013 Mar; 19(3):410-7. Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB. PMID: 23128322; PMCID: PMC4077191.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    156. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant. 2012 Nov; 18(11):1677-86. Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. PMID: 22643322; PMCID: PMC4010147.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    157. Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant. Leuk Lymphoma. 2012 Aug; 53(8):1525-9. Beitinjaneh AM, Saliba R, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Anderlini P, Dinh Y, Qureshi S, Rondon G, Champlin RE, Giralt SA, Qazilbash MH. PMID: 22242817.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    158. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol. 2012 Mar; 87(3):272-6. Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. PMID: 22231283; PMCID: PMC3894831.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    159. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer. 2012 Jul 15; 118(14):3549-55. Shah N, Ahmed F, Bashir Q, Qureshi S, Dinh Y, Rondon G, Wen S, Thall P, Khan H, Giralt S, Champlin R, Qazilbash MH. PMID: 22086552; PMCID: PMC4038445.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    160. Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. Leuk Lymphoma. 2012 Jan; 53(1):50-6. Shah N, Cabanillas F, McIntyre B, Feng L, McLaughlin P, Rodriguez MA, Romaguera J, Younes A, Hagemeister FB, Kwak L, Fayad L. PMID: 21895545; PMCID: PMC4104165.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    161. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer. 2012 May 01; 118(9):2507-15. Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. PMID: 21887685; PMCID: PMC4015116.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    162. Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma. Leuk Lymphoma. 2012 Jan; 53(1):118-22. Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. PMID: 21780997.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    163. Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma. Cancer Res. 2011 Jul 15; 71(14):5040-9. Yang H, Robinson SN, Nieto Y, Jones RJ, Gocke CD, Lu J, Giralt SA, Jones RB, Decker WK, Xing D, Steiner D, Champlin RE, McMannis JD, Ng J, Thomas MW, Shah N, Andersson BS, Parmar S, Shpall EJ. PMID: 21646477.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    164. Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion. J Immunother. 2010 Sep; 33(7):684-96. Xing D, Ramsay AG, Gribben JG, Decker WK, Burks JK, Munsell M, Li S, Robinson SN, Yang H, Steiner D, Shah N, McMannis JD, Champlin RE, Hosing C, Zweidler-McKay PA, Shpall EJ, Bollard CM. PMID: 20664358; PMCID: PMC3530422.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    165. Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation. Hematology Am Soc Hematol Educ Program. 2010; 2010:310-3. Shah N, Lonial S. PMID: 21239811; PMCID: PMC4086196.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    166. NK antibody therapy: KIR-ative intent. Blood. 2009 Sep 24; 114(13):2567-8. Shah N, Shpall EJ. PMID: 19779042.
      View in: PubMed   Mentions: 1     Fields:    
    167. The challenge of providing infertility services to a low-income immigrant Latino population. Fertil Steril. 2009 Jul; 92(1):116-23. Nachtigall RD, Castrillo M, Shah N, Turner D, Harrington J, Jackson R. PMID: 18710703; PMCID: PMC2722953.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    Nina's Networks
    Concepts (406)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (54)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-5-g94c7c43e on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.